TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05372991
Drug: CBT-009
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study: NCT05372991
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a Two-Stage Phase 1/2 study to evaluate the safety, tolerability and pharmacodynamics of CBT-009 eye drop in healthy volunteers.
Study: NCT06393504
Drug: Non-orexin receptor antagonist insomnia medication
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-orexin receptor antagonist insomnia medication received during or shortly prior to pregnancy.
Study: NCT05141110
Drug: NVP-1705-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP-1705-R
Study: NCT06025214
Drug: ADVAIR DISKUS® 500/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations in one study period
Study: NCT06380491
Drug: Melatonin 3 MG Oral Tablet
Normalized name: melatonin 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with OSA and nocturnal non-dipping Blood Pressure will be randomly assigned to a treatment with melatonin 3mg/d or to receive only the usual care.
Study: NCT06267846
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration
Study: NCT06322628
Drug: VSA006
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 12 weeks, subcutaneous injections
Study: NCT06322628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 12 weeks, subcutaneous injections
Study: NCT05431673
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100mg/day for 6 weeks used as single or combination treatment for Rhinoscleroma
Study: NCT00002110
Drug: Cysteamine
Normalized name: Cysteamine
DrugBank: Cysteamine (DB00847)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05804669
Drug: CRN04894
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRN04894 is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.
Study: NCT06447870
Drug: biologic therapy(eg:IFX,ADA,UST,VDZ)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients received biologic therapy during the baseline period, and the specific type of medication was determined based on the professional doctor's diagnosis and treatment opinions. Patients were then divided into two groups based on whether primary non-response occurred or not.
Study: NCT06243536
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not assigned to receive semaglutide will receive standard of care.
Study: NCT05794204
Drug: RMP-A03 - Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will randomized to low dose of RMP-A03
Study: NCT05794204
Drug: RMP-A03 - Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to high dose of RMP-A03
Study: NCT05794204
Drug: RMP-A03 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to RMP-A03 Placebo
Study: NCT06061926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Study: NCT04311099
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Ropivacaine
Study: NCT04311099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Saline solution
Study: NCT04792645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill that contains no medicine
Study: NCT04649229
Drug: LCZ 696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with LCZ696 is unblinded in this study. After the two acute study days, subjects will be provided LCZ696 50 mg bid for two weeks. At the end of those two weeks subjects will report to the Clinical Research Center (CRC) for a dose escalation visit. If their tolerance, blood pressure, potassium, and eGFR meet escalation criteria they will be given LCZ696 100 mg bid for three weeks. (If they do not meet escalation criteria they will be continued on LCZ696 50 mg bid.) After three weeks, they will return to the CRC for the next escalation visit. If they meet criteria for escalation they will be given LCZ 200 mg bid for ten days. (If they do not meet escalation criteria they will be continued on the highest tolerated dose).
Study: NCT04649229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or aprepitant 120 mg will be given orally on study days 1 and 2 and again on study days 3 and 4
Study: NCT06603688
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin 500mg, twice daily for 14 days.
Study: NCT06603688
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline 100 mg, twice daily for 14 days
Study: NCT06176222
Drug: PRECEDEX INJ★ 2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient received PRECEDEX INJ★ 2ML 0.1\~0.4 mcg/kg/hr intravenous infusion 12 hours after the surgery immediately
Study: NCT06655259
Drug: Standard Medical Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive Standard Medical Therapy, which includes ADT, typically with an LHRH agonist or antagonist, to reduce testosterone levels, a key driver of prostate cancer progression. In addition to ADT, participants may be treated with second-generation anti-androgen drugs such as Abiraterone or Enzalutamide. These medications block androgen receptor signaling and further inhibit the cancer\&#39;s ability to grow.
Study: NCT06592638
Drug: ZG006
Normalized name: Zoledronic acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ZG006 will be administered as an intravenous (IV) infusion.
Study: NCT05074290
Drug: Epidiferphane
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the phase I portion of the study, subjects will be assigned to take either two (half target dose) or four (full target dose) Epidiferphane tablets orally three times daily following a 3 + 3 design. Three subjects will be sequentially enrolled at each of the 2 dose levels (beginning with the half target dose) until at least one dose-limiting toxicity (DLT) occurs. Dosing escalation will be stopped if two or more DLTs occur at either dose level. The maximum tolerated dose will be one dose level lower than the dose level at which 2 or more DLTs occur. Dose escalation will occur separately for each taxane regimen (docetaxel or paclitaxel).~All subjects in the phase II portion of the study will receive the maximum tolerated dose determined in the phase I portion of the study for their taxane regimen.~Subjects in both portions of the study will receive treatment with Epidiferphane for a maximum of three months.
Study: NCT05074290
Drug: Taxane Chemotherapy
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects on both phases of the study will be concurrently treated with a taxane regimen containing either paclitaxel given weekly, nab-paclitaxel given weekly or every 3 weeks or docetaxel given every 3 weeks. The choice of taxane regimen will be determined by the treating physician prior to consenting to participate in this trial.
Study: NCT04691570
Drug: ANX005
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANX005 is provided as a solution for IV infusion
Study: NCT05584007
Drug: Placebo Only Product in Oral Dose Form
Normalized name: placebo Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be prescribed flucloxacillin 500mg QDS for 5 days followed by a blinded placebo for 2 days, reaching a total of 5 days of antibiotic treatment
Study: NCT05605366
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minocycline is a second-generation tetracycline antibiotic with good central nervous system penetration and anti-neuroinflammatory effect.
Study: NCT05605366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is capsule that is identical in size and appearance as the drug, but without active drug ingredient.
Study: NCT05180773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.
Study: NCT05180773
Drug: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),
Study: NCT06595797
Drug: HRS9531
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531
Study: NCT06595797
Drug: HRS9531placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531placebo
Study: NCT06591845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Suspension, Route of Administration: Oral
Study: NCT06596161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05978167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo pill
Study: NCT06073938
Drug: NHWD-870
Approvals — FDA: no, EMA: no, PMDA: no
Description: The base dosage administered is 2.0 mg/dose/day, and the frequency and dose of administration may be adjusted based on safety data.
Study: NCT05796401
Drug: Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised neuroprotective medication adapted to the individual's biological profile :~* Vitamin B12 : 500 micrograms per day~* Folinic acid : 50 mg per day~* Omega 3 : 1380 mg EicosaPentaenoic Acid (EPA) + 1140 mg DocosaHexaenoic Acid (DHA) per day~* N-acetyl-cysteine (NAC) : 2400 mg per day~duration of supplementation(s) : 12 weeks
Study: NCT06585852
Drug: Xenograft
Normalized name: Xenograft heart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaffold material of choice
Study: NCT05710367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched oral drug. Placebo tablet will have the same color, taste, smell and package as the verum tablet
Study: NCT06587425
Drug: LM-302+Candonilimab+Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.
Study: NCT05078047
Drug: Reduced dose intensity of IO
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
Study: NCT05469386
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT04931563
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion (IV)
Study: NCT06371092
Drug: UltraEZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the UltraEZ gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study: NCT06371092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of individualized bleaching trays and a position-finder tray of both arches. Application of the placebo gel in the bleaching trays for 30 minutes. Application of the bleaching gel in the bleaching trays during 6-8 hours
Study: NCT05642403
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched inhaled placebo
Study: NCT05797467
Drug: FOLFOX chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.
Study: NCT04732221
Drug: MK-5475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 (soluble guanylate cyclase stimulator) 380 µg, 100 µg or 32 µg administered as dry powder inhalation
Study: NCT04732221
Drug: Placebo to MK-5475
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as dry powder inhalation
Study: NCT06509880
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Day 1-2: Oxaliplatin 100 mg/m2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m2 (or levoleucovorin 200 mg/m2) IV infusion, followed by 5-FU 400 mg/m2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m2 for first two cycles, and may be increased to 3000 mg/m2 if tolerated by patient (no toxicity \> grade 1 during the first two cycles), days 3-14: Rest days)
Study: NCT05587933
Drug: Antispasmodic
Normalized name: Antispasmodic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antispasmodic
Study: NCT05843643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04682366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug: 10 days of identical-appearing placebo
Study: NCT05429008
Drug: HMPL-A83 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1,8,15,22 dose; 28 day treatment cycles.
Study: NCT04098718
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg tablet daily for 5 days
Study: NCT05477823
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care ADT
Study: NCT06516978
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06516978
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Study: NCT06775860
Drug: ICP-332 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-332 will be administered as tablet
Study: NCT06502002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline infusion
Study: NCT06775860
Drug: ICP-332 Placebo Tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-332 Placebo will be administered as tablet
Study: NCT06722820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02864784
Drug: Amorphous calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
Study: NCT05975684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day for 4 weeks
Study: NCT05614544
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 for induction of general anesthesia
Study: NCT05614544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid
Study: NCT05570669
Drug: (Macrogol 4000 52,500 g + Sodium sulphate anhydrous 3,750 g + Simethicone 0,080 g) split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taking the colonoscopy preparation drug (Clensia) in two stages of administration
Study: NCT05006638
Drug: Lipid Emulsion, Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
Study: NCT05006638
Drug: Toxogonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: a drug used as an antidote for some types of pesticides
Study: NCT06269432
Drug: Precision Antiplatelet Therapy Trial Group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.
Study: NCT06269432
Drug: Traditional Antiplatelet Therapy Control Group
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
Study: NCT04978675
Drug: Fluorine F 18 rhPSMA-7.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05028569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT06050928
Drug: Oral EP262
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT04882202
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1g IV every 6 hours for a weight \> 50kg (maximum of 4g per 24 hours) or 15mg/kg every 6 hours for a weight \< 50kg (maximum of 75mg/kg per 24 hours)
Study: NCT04684277
Drug: antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: depression recieve antidepressant treatment
Study: NCT06781281
Drug: NabPE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 75mg/m2 ivgtt +Albumin Paclitaxel 260mg/m2
Study: NCT06326060
Drug: NNC0519-0130
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT06326060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT05174416
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching PBO capsules during placebo controlled period，and mavacamten capsules during long term extension period
Study: NCT05348213
Drug: Chidamide plus R-ICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chidamide 20mg/d PO D1、4、8、11 Rituximab 375mg/m2 IV D0 Ifosfamide 1500mg/m2 IV D1-3 Carboplatin AUC×\[GFR(ml/min) + 25\] mg/d,AUC=5 IV D2 Etoposide 100 mg/m2 IV D1-3
Study: NCT05004285
Drug: [F-18]Florastamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of \[F-18\]Florastamin at 10 ± 1 mCi is IV administered at Visit 2, and \[F-18\]Florastamin PET/CT images are obtained from the head to thigh after 110 ± 10 minutes.
Study: NCT06655012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered placebo (8 puffs) from a MDI device
Study: NCT05174013
Drug: GSK3858279
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 will be administered
Study: NCT05174013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered
Study: NCT04885218
Drug: SHR-1209 ;placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1209 and placebo 150 mg subcutaneous injection once every 4 weeks for 48 weeks
Study: NCT04885218
Drug: SHR-1209 ;placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1209 and placebo 300 mg subcutaneous injection once every 8 weeks for 48 weeks
Study: NCT04885218
Drug: SHR-1209 ;placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1209 and placebo 450 mg subcutaneous injection once every 12 weeks for 48 weeks
Study: NCT06601595
Drug: TNF inhibitors
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: tumour necrosis factor inhibitors approved as treatments for ulcerative colitis and/or Crohns disease
Study: NCT06601595
Drug: conventional ibd medical treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies for ulcerative colitis and Crohns disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate other than anti-tumor necrosis factor agents.
Study: NCT06593782
Drug: HSK21542
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. HSK21542 injection was administered day 1;~2. Placebo to match Dorasetron was administered on day 1;~3. Aprepitant injection was administered on day 1;~4. Dexamethasone tablets was administered on day 1 to day 4;
Study: NCT06219499
Drug: ONC-841
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC-841 is a humanized monoclonal antibody.
Study: NCT05776407
Drug: ThisCART19A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Allogeneic Anti-CD19 CAR T cells (ThisCART19A) will be infused after the lymphodepletion conditioning of Fludarabine, Cyclophosphamide and Etoposide.
Study: NCT05776407
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT05406466
Drug: Cryoablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoablation will be performed with a two-cycle freeze-thaw phase protocol; US or non-contrast CT images will be obtained to visualize the evolving ablation zone
Study: NCT04629209
Drug: ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 is a orally active, small molecule DRD2 antagonist that kills cancer cells but not normal cells.
Study: NCT02014428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no